Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02704273 · ClinicalTrials.gov registry record
A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects
A clinical trial, sponsored by Astellas Gene Therapies.
- Completed
- Registry status
- 34
- Enrollment target
NCT02704273: Completed study, sponsored by Astellas Gene Therapies.
NCT02704273 is a clinical trial that has completed, run by Astellas Gene Therapies. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02704273 has completed, sponsored by Astellas Gene Therapies.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
This is a pre-Phase 1 prospective, non interventional clinical assessment study to evaluate XLMTM subjects aged 3 years and younger. Many of these clinically relevant measures have not yet been routinely assessed in this population and may provide important insight on the natural history of XLMTM and for future evaluation of potential therapies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-09 |
What the finished NCT02704273 record still lists
NCT02704273 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02704273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02704273 about?
NCT02704273 is a clinical study titled "A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects". This is a pre-Phase 1 prospective, non interventional clinical assessment study to evaluate XLMTM subjects aged 3 years and younger. Many of these clinically relevant measures have not yet been routinely assessed in this population and may provide important insight on the natural history of XLMTM an...
What is the current status of trial NCT02704273?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2016-07. Estimated completion is 2019-09.
Who is sponsoring clinical trial NCT02704273?
This trial is sponsored by Astellas Gene Therapies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia